Chronic Pancreatitis

Chronic pancreatitis is a progressive, relapsing inflammatory disease of the exocrine pancreas characterized by irreversible morphological changes, including acinar cell loss, fibrosis, and mononuclear inflammatory infiltration. Unlike acute pancreatitis, which is typically reversible, chronic pancreatitis leads to permanent structural and functional damage, often culminating in exocrine pancreatic insufficiency (EPI) and, less commonly, endocrine dysfunction (diabetes mellitus). The disease is recognized in both dogs and cats, with distinct etiologies and clinical presentations. In dogs, chronic pancreatitis may be a sequel to recurrent acute episodes or may develop insidiously without clinically apparent acute attacks. In cats, chronic pancreatitis is frequently associated with inflammatory bowel disease (IBD) and cholangitis, forming the 'triaditis' complex. The condition is often underdiagnosed due to vague clinical signs and the limitations of routine diagnostic tests.

The etiology of chronic pancreatitis is multifactorial and often idiopathic. In dogs, potential causes include dietary indiscretion (high-fat meals), hyperlipidemia (especially in breeds like Miniature Schnauzers), genetic predispositions (e.g., mutations in the SPINK1 or PRSS1 genes, though not fully characterized in veterinary medicine), autoimmune mechanisms (lymphocytic-plasmacytic pancreatitis), and recurrent acute pancreatitis leading to chronic changes. In cats, chronic pancreatitis is commonly associated with concurrent inflammatory bowel disease (IBD) and cholangiohepatitis, suggesting an immune-mediated or infectious etiology (e.g., Toxoplasma gondii, feline coronavirus). Other potential causes include pancreatic duct obstruction (e.g., from neoplasia or parasites), trauma, ischemia, and certain drugs (e.g., azathioprine, L-asparaginase). In both species, chronic pancreatitis may also be a consequence of metabolic disorders such as hypercalcemia, hypertriglyceridemia, and uremia. However, in many cases, no definitive cause is identified.

Chronic pancreatitis occurs in both dogs and cats, with no strong sex predilection. In dogs, middle-aged to older animals are more commonly affected, with a median age of around 7-9 years. Certain breeds are predisposed, including Miniature Schnauzers (due to hyperlipidemia), English Cocker Spaniels, Cavalier King Charles Spaniels, and Boxers. In cats, chronic pancreatitis is often diagnosed in middle-aged to older cats, with a median age of 7-10 years. No specific breed predilection is consistently reported, but domestic shorthair cats are common. The prevalence is difficult to estimate due to subclinical cases, but post-mortem studies suggest that chronic pancreatitis may be present in up to 1-2% of dogs and 1.5-3% of cats. Concurrent diseases, particularly IBD and cholangitis in cats, are frequently present. Geographic variations are not well-documented, but dietary and environmental factors may influence incidence.

The pathophysiology of chronic pancreatitis involves a complex interplay of genetic, environmental, and immune factors leading to progressive acinar cell injury and death. The initial insult triggers an inflammatory cascade with infiltration of mononuclear cells (lymphocytes, plasma cells, macrophages) into the pancreatic parenchyma. This is followed by activation of pancreatic stellate cells, which transform into myofibroblast-like cells that produce excessive extracellular matrix, resulting in fibrosis. The fibrotic process disrupts normal pancreatic architecture, leading to acinar cell atrophy and loss of exocrine function. Additionally, inflammatory mediators such as cytokines (TNF-α, IL-1, IL-6) and growth factors (TGF-β) perpetuate the inflammatory response and promote fibrosis. Over time, the pancreatic ducts may become stenotic or obstructed, further exacerbating acinar damage. Endocrine dysfunction may occur due to destruction of islet cells, leading to diabetes mellitus. In cats, the close anatomical relationship between the pancreatic duct and the common bile duct may facilitate the spread of inflammation to the biliary tree, contributing to triaditis. The systemic effects of chronic inflammation may include weight loss, malnutrition, and, in severe cases, systemic inflammatory response syndrome (SIRS).

Predisposing factors for chronic pancreatitis include genetic susceptibility (e.g., certain breeds like Miniature Schnauzers with hyperlipidemia), hypertriglyceridemia, hypercalcemia, obesity, high-fat diets, and concurrent endocrine disorders such as diabetes mellitus and hypothyroidism. In cats, concurrent inflammatory bowel disease and cholangitis are significant risk factors. Chronic use of certain medications (e.g., azathioprine, L-asparaginase, potassium bromide) may also predispose to pancreatic inflammation. Age is a risk factor, with older animals more commonly affected. Additionally, recurrent acute pancreatitis can progress to chronic disease. Environmental factors such as dietary indiscretion and exposure to toxins (e.g., organophosphates) may also contribute. Immunosuppression, whether due to disease or therapy, may increase susceptibility to infectious causes, particularly in cats.

Clinical signs of chronic pancreatitis are often vague and intermittent, and may include recurrent or persistent vomiting, diarrhea (often steatorrhea in advanced cases), anorexia, weight loss, lethargy, and abdominal pain. In dogs, signs may be mild and episodic, with some animals showing only poor body condition or greasy stools. In cats, signs are frequently subtle, with anorexia and weight loss being the most common; vomiting may be less frequent. Physical examination may reveal dehydration, pale mucous membranes, icterus (if concurrent biliary disease), and a palpable abdominal mass or pain on abdominal palpation. In advanced cases, signs of exocrine pancreatic insufficiency (EPI) such as chronic diarrhea, steatorrhea, and poor coat quality may be evident. Endocrine dysfunction may manifest as polyuria, polydipsia, and weight loss if diabetes mellitus develops. Some animals may be asymptomatic, with chronic pancreatitis discovered incidentally on imaging or necropsy.

Differential diagnoses for chronic pancreatitis include: (1) Acute pancreatitis – distinguished by acute onset, more severe clinical signs, and elevated pancreatic lipase; chronic cases may have a history of recurrent episodes. (2) Exocrine pancreatic insufficiency (EPI) – characterized by chronic diarrhea, weight loss, and low serum TLI; may be a sequela of chronic pancreatitis. (3) Inflammatory bowel disease (IBD) – presents with chronic vomiting, diarrhea, and weight loss; diagnosis via intestinal biopsy and response to dietary/immunosuppressive therapy. (4) Hepatic disease (e.g., cholangitis, hepatitis) – may cause similar signs, especially in cats; liver enzyme elevations and imaging findings help differentiate. (5) Gastrointestinal neoplasia (e.g., lymphoma, adenocarcinoma) – may cause weight loss, vomiting, and abdominal masses; imaging and biopsy are necessary. (6) Chronic renal disease – can cause vomiting, anorexia, and weight loss; renal parameters and urinalysis are key. (7) Diabetes mellitus – may be a consequence of chronic pancreatitis but can also present with similar signs; blood glucose and fructosamine levels. (8) Biliary obstruction (e.g., from cholelithiasis or neoplasia) – may cause icterus and vomiting; imaging and liver enzymes. (9) Peritonitis – acute abdomen, fever, and systemic signs; abdominal fluid analysis. (10) Parasitic infections (e.g., toxoplasmosis in cats) – may cause pancreatitis and other systemic signs; serology and PCR.

The diagnostic approach to chronic pancreatitis begins with a thorough history and physical examination. Initial screening includes a complete blood count (CBC), serum biochemistry profile, and urinalysis. If pancreatitis is suspected, a specific pancreatic lipase test (cPLI for dogs, fPLI for cats) is recommended; a normal result makes chronic pancreatitis unlikely, while an elevated result supports the diagnosis. Abdominal ultrasonography is the next step to evaluate pancreatic morphology, looking for an irregular, hypoechoic or hyperechoic pancreas, dilation of the pancreatic duct, and peripancreatic fat changes. If ultrasound is inconclusive, computed tomography (CT) may be considered, though it is less commonly used in veterinary medicine. Definitive diagnosis often requires pancreatic biopsy, either via ultrasound-guided fine-needle aspiration (cytology) or surgical biopsy (histopathology). However, biopsy is invasive and may be reserved for cases where the diagnosis is uncertain or when concurrent diseases are suspected. In cats, a full gastrointestinal workup, including intestinal biopsy, is often warranted due to the high prevalence of triaditis. Additional tests may include serum folate and cobalamin levels to assess for concurrent intestinal disease, and measurement of trypsin-like immunoreactivity (TLI) to evaluate exocrine function.

Hematology may show a mild leukocytosis or, in chronic cases, no significant changes. Serum biochemistry may reveal mild to moderate elevations in liver enzymes (ALT, ALP) if concurrent hepatobiliary disease is present. Hyperbilirubinemia may occur with biliary obstruction. Pancreatic enzyme elevations (amylase, lipase) are often not consistently elevated in chronic pancreatitis; therefore, specific pancreatic lipase immunoreactivity (cPLI/fPLI) is more sensitive and specific. Serum trypsin-like immunoreactivity (TLI) may be normal or low; low TLI indicates exocrine pancreatic insufficiency. In cats, concurrent IBD may cause decreased cobalamin and increased folate levels. Blood glucose may be elevated if diabetes mellitus has developed. Electrolyte imbalances (e.g., hypokalemia) may occur due to vomiting or diarrhea. In severe cases, a systemic inflammatory response may be reflected by elevated C-reactive protein (CRP) or other acute-phase proteins. Urinalysis is usually unremarkable, but may show glucosuria if diabetes is present. In cases of suspected infectious etiology, serology or PCR for Toxoplasma or feline coronavirus may be performed.

Abdominal radiography is often unremarkable in chronic pancreatitis, but may show a loss of serosal detail in the cranial abdomen if peritonitis is present. Ultrasonography is the primary imaging modality. Findings may include an irregular pancreatic contour, decreased or increased echogenicity (often hypoechoic due to fibrosis), a dilated pancreatic duct, and hyperechoic mesentery surrounding the pancreas. In cats, concurrent changes in the liver (e.g., hyperechoic parenchyma, biliary sludge) and intestines (e.g., thickened walls) may be seen. Doppler ultrasound may show increased vascularity in acute phases but is not specific. Computed tomography (CT) provides better resolution and may detect subtle changes, but is less commonly available. Magnetic resonance imaging (MRI) is rarely used but can provide detailed soft tissue contrast. Endoscopic retrograde cholangiopancreatography (ERCP) is not routinely performed in veterinary medicine. In cases of suspected pancreatic neoplasia, contrast-enhanced ultrasound or CT may be helpful.

Fine-needle aspiration (FNA) of the pancreas can be performed under ultrasound guidance. Cytology may reveal inflammatory cells (lymphocytes, plasma cells, macrophages) and acinar cells with degenerative changes. However, FNA has low sensitivity for chronic pancreatitis due to the patchy nature of the disease. Histopathology from surgical biopsy is the gold standard. Findings include acinar cell atrophy, fibrosis, mononuclear inflammatory infiltration (lymphocytes, plasma cells), and ductal changes such as hyperplasia or metaplasia. In cats, lymphocytic-plasmacytic infiltration is common. Special stains such as Masson's trichrome can highlight fibrosis. The severity of fibrosis and inflammation can be graded, which may correlate with clinical signs and prognosis. Biopsy is essential to rule out neoplasia, especially in older animals.

Treatment of chronic pancreatitis focuses on managing clinical signs, preventing progression, and addressing complications. In acute flares, supportive care includes intravenous fluid therapy with balanced crystalloids (e.g., lactated Ringer's solution) at rates to correct dehydration and maintain perfusion (e.g., 60-100 ml/kg/day in dogs, 40-60 ml/kg/day in cats, adjusted based on losses). Analgesia is crucial; opioids such as buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) or fentanyl CRI (2-5 mcg/kg/h) are preferred. Antiemetics such as maropitant (1 mg/kg IV/SC q24h) or ondansetron (0.5-1 mg/kg IV q12h) are indicated for vomiting. Nutritional support is important; early enteral feeding via nasoesophageal or esophagostomy tube is recommended if the animal is anorexic for >3 days. A low-fat, highly digestible diet is ideal. In chronic cases, management includes dietary modification (low-fat, high-fiber), pancreatic enzyme supplementation if EPI develops (e.g., pancreatic enzyme powder at 1-2 teaspoons per meal), and treatment of diabetes mellitus if present. Corticosteroids (e.g., prednisolone 0.5-1 mg/kg PO q12h) may be used in cases of suspected immune-mediated pancreatitis, particularly in cats, but should be used cautiously. Antibiotics are not routinely indicated unless there is evidence of bacterial infection. Surgical intervention may be necessary for complications such as pancreatic abscess or obstruction. Long-term follow-up is essential.

The prognosis for chronic pancreatitis is variable and depends on the underlying cause, severity of fibrosis, and presence of complications. Many animals can be managed successfully with dietary changes and supportive care, but the disease is progressive. In dogs, the prognosis is generally good if EPI and diabetes are managed appropriately, but recurrent flares may occur. In cats, the prognosis is more guarded, especially if concurrent IBD and cholangitis are present; however, with aggressive management, some cats can have a good quality of life. Negative prognostic indicators include severe weight loss, development of diabetes mellitus, and lack of response to therapy. Mortality rates are not well-defined but are higher in animals with severe systemic complications. Regular monitoring and early intervention can improve outcomes.

Follow-up for chronic pancreatitis involves regular re-evaluations every 1-3 months initially, then every 6-12 months if stable. Monitoring should include serial measurements of cPLI/fPLI, serum biochemistry, and body weight. Abdominal ultrasound may be repeated to assess progression of fibrosis or development of complications. If EPI is present, serum TLI and cobalamin levels should be monitored periodically. For diabetic animals, blood glucose curves and fructosamine levels are recommended. Dietary compliance is crucial; owners should be educated on the importance of a low-fat diet. Adjustments to pancreatic enzyme replacement therapy may be needed based on clinical response. In cats, concurrent IBD and cholangitis require ongoing management, including periodic intestinal biopsies if indicated. Owners should be advised to seek immediate veterinary care if signs of an acute flare (vomiting, anorexia, abdominal pain) occur.

Pearls: (1) Chronic pancreatitis can be subclinical; consider it in any older dog or cat with unexplained weight loss or chronic vomiting. (2) cPLI/fPLI is the most sensitive blood test; a normal result makes pancreatitis unlikely. (3) In cats, always evaluate for concurrent IBD and cholangitis (triaditis). (4) Early enteral nutrition is beneficial; do not fast for prolonged periods. (5) Pancreatic enzyme replacement is essential if EPI develops; use powder form for better efficacy. Pitfalls: (1) Relying on serum amylase and lipase; they are unreliable in chronic pancreatitis. (2) Overlooking concurrent diabetes mellitus; check blood glucose and fructosamine. (3) Using corticosteroids indiscriminately; they may worsen pancreatic inflammation if infection is present. (4) Failing to perform a biopsy when neoplasia is suspected; chronic pancreatitis can mimic pancreatic adenocarcinoma. (5) Not adjusting drug dosages in renal or hepatic impairment; many drugs require dose reduction.

Analgesics: Buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) or fentanyl CRI (2-5 mcg/kg/h) for moderate to severe pain. Antiemetics: Maropitant (1 mg/kg IV/SC q24h) or ondansetron (0.5-1 mg/kg IV q12h). Gastroprotectants: Omeprazole (0.7-1 mg/kg PO q24h) or famotidine (0.5-1 mg/kg IV/PO q12h) if gastric ulceration is suspected. Corticosteroids: Prednisolone (0.5-1 mg/kg PO q12h) for suspected immune-mediated pancreatitis, tapering over weeks. Antibiotics: Not routinely indicated; if bacterial infection is documented, choose based on culture and sensitivity (e.g., ampicillin 20 mg/kg IV q8h). Pancreatic enzyme replacement: Pancreatic enzyme powder (1-2 teaspoons per meal) for EPI. Cobalamin supplementation: For hypocobalaminemia, administer 250-500 mcg SC weekly for 6 weeks, then monthly. Insulin therapy: For diabetes mellitus, use NPH insulin (0.25-0.5 U/kg SC q12h) with dose adjustments based on glucose curves. Fluid therapy: Balanced crystalloids (e.g., lactated Ringer's) at maintenance (60-100 ml/kg/day in dogs, 40-60 ml/kg/day in cats) plus deficits. All dosages should be adjusted based on renal/hepatic function and clinical response.

Evidence-based literature on chronic pancreatitis in dogs and cats is limited. A landmark study by Xenoulis and Steiner (2008) reviewed the use of cPLI and fPLI in diagnosing pancreatitis, showing high sensitivity and specificity. A consensus statement by the ACVIM (2012) on pancreatitis in dogs and cats recommended the use of pancreatic lipase immunoreactivity as the preferred biomarker. Studies have shown that chronic pancreatitis is often associated with concurrent diseases, particularly in cats (e.g., triaditis). A study by Simpson et al. (2011) found that cats with chronic pancreatitis had a high prevalence of IBD and cholangitis. Treatment recommendations are largely extrapolated from human medicine and expert opinion. A randomized controlled trial by Mansfield et al. (2011) evaluated early enteral nutrition in dogs with acute pancreatitis, showing improved outcomes; this is likely applicable to chronic flares. There is a lack of large-scale clinical trials for chronic pancreatitis specifically, highlighting the need for further research.